Updated:
Clinical Ink
Clinical Ink is a technology provider whose founding year and ownership structure are not publicly disclosed.
Clinical Ink
Clinical Ink is a technology provider whose founding year and ownership structure are not publicly disclosed. The firm operates from Winston-Salem, NC, with an additional office in Horsham, PA. The company's eSource platform ingests data from multiple sources—Direct Data Capture (DDC), electronic Clinical Outcome Assessments (eCOA), eConsent, telehealth, sensors, wearables, and digital biomarkers—to support decentralized clinical trials. It focuses on therapeutic areas including neurology, infectious disease, immunology, and oncology. The firm has developed specific tools such as GlucoseReady™ for diabetes and weight management, and the eLAS® Suite for lupus trials (per the firm's website). Over the past three years, Clinical Ink reports tripling bookings, quadrupling revenues, and growing backlog by 500% (per the firm). In recent months, the company announced Kaitality™, a digital tool for drug adherence and weight management, and SPUR™, an adherence solution for cardiometabolic disease management. It also appointed Dr. Christian Born Djurhuus as Chief Science Officer. Clinical Ink's structural differentiator lies in its eSource ecosystem designed to consolidate all trial data—regardless of source—into a single analytics platform. This architecture is built to shift the industry toward direct-from-patient data capture, distinguishing it from point-solution eCOA providers.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Winston-Salem
Corporate office
119 Brookstown Ave, Ste 101, Winston-Salem, NC 27101, United States
Additional offices
Horsham, PA
Principals
Christian Born Djurhuus
Chief Science Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Clinical Ink?
Clinical Ink's leadership is not publicly named beyond the appointment of Dr. Christian Born Djurhuus as Chief Science Officer (per the firm's website, 2025). The firm does not disclose its board or executive team on its site.
How does Clinical Ink source proprietary deal flow?
Clinical Ink is a technology company, not an investment firm. It sources business through direct sales to sponsors and CROs, and its pipeline is driven by the need for decentralized clinical trial technology (per the firm's website).
Is Clinical Ink structured as a single family office or does it operate more like a venture firm?
Clinical Ink operates as a commercial technology company providing eSource clinical trial software. Its ownership structure is not publicly disclosed; there is no evidence it functions as a family office or investment vehicle.
Does Clinical Ink participate in fund commitments or only direct deals?
Clinical Ink is a product company that sells eSource platforms and services to sponsors and CROs. It does not make fund commitments or direct investments.
What therapeutic areas does Clinical Ink support?
Clinical Ink focuses on neurology, infectious disease, immunology (including lupus), oncology, and diabetes (per the firm's website). Its tools are designed for complex therapies requiring decentralized data collection.
Does Clinical Ink maintain philanthropic structures, and how are they separated?
Clinical Ink does not publicly disclose any philanthropic structures or foundations. Its activities are strictly commercial.
What is Clinical Ink's known posture on co-investments alongside external GPs?
Clinical Ink is not an investment firm and does not participate in co-investments alongside external GPs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: